Kyleena 19.5 mg intrauterine delivery system

  • Name:

    Kyleena 19.5 mg intrauterine delivery system

  • Company:
    info
  • Active Ingredients:

    Levonorgestrel

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/10/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 7/7/2020

Click on this link to Download PDF directly

Bayer Limited

Bayer Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adalat LA 20 Active Ingredients Nifedipine
Medicine Name Adalat LA 30 Active Ingredients Nifedipine
Medicine Name Adalat LA 60 Active Ingredients Nifedipine
Medicine Name Alka Seltzer Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin), Citric Acid, Sodium Hydrogen Carbonate
Medicine Name Androcur 100 Active Ingredients Cyproterone Acetate
Medicine Name Angeliq 1 mg / 2 mg film-coated tablets Active Ingredients Drospirenone, Estradiol Hemihydrate
Medicine Name Aspirin 300mg Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name Avelox 400mg Film-coatedTablets Active Ingredients Moxifloxacin hydrochloride
Medicine Name Avelox 400mg/250ml Solution for Infusion Active Ingredients Moxifloxacin hydrochloride
Medicine Name Bepantiseptic First Aid Cream Active Ingredients Chlorhexidine digluconate, Phenol
Medicine Name Betaferon 250 microgram/ml, powder and solvent for solution for injection Active Ingredients Interferon beta-1b
Medicine Name Canesten 200mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten 500mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten Combi Pessary and Cream Active Ingredients Clotrimazole
Medicine Name Canesten Cream Active Ingredients Clotrimazole
Medicine Name Canesten Duopak Active Ingredients Clotrimazole
Medicine Name Canesten HC Cream Active Ingredients Clotrimazole, Hydrocortisone
Medicine Name Canesten Soft Vaginal Capsule Combi Active Ingredients Clotrimazole
Medicine Name Canesten Thrush Cream Active Ingredients Clotrimazole
Medicine Name Ciproxin 500mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 750mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin Solution for Infusion 2mg/ml, 200ml Active Ingredients Ciprofloxacin
Medicine Name Clarityn 10 mg Tablets Active Ingredients Loratadine
Medicine Name Cystopurin 3g Granules for Oral Solution Active Ingredients Potassium Citrate
Medicine Name Dianette 2mg/35 micrograms coated tablets Active Ingredients Cyproterone Acetate, Ethinylestradiol
1 - 0 of 65 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 October 2020 Ed-Both

Reasons for updating

  • Add New Doc

Updated on 5 October 2020 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Free text change information supplied by the pharmaceutical company

The start of the PIL

Deletion of Patient's name, Doctor's name, Doctor's phone number, Date of insertion, Latest date of removal, First check up visit and Next visits: 1, 2, 3, 4, 5.

 

Section 6

Deletion of Croatia from the list of member states of the EEA.

 

Section 6 - date of revision

This leaflet was last revised in July 2020September 2020.

 

Change to information for healthcare professionals

Summary of Product Characteristics for Kyleena online at www.pi.bayer.com/kyleena/ie

(Addition of website address).

 

Updated on 21 August 2020 Ed-HCP

Reasons for updating

  • Add New Doc

Free text change information supplied by the pharmaceutical company

HCP brochure containing information re differentiation between Bayer's LNG-IUDs and ectopic pregnancy

Updated on 7 July 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

To implement the outcome of the finished PSUSA procedure of all levonorgestrel-containing products (PSUSA/00001856/ 201905). For Kyleena additional wording for SmPC section 4.8 and PL section 3 and 4 has to be introduced.

The HPRA details for the reporting of side effects have also been updated.

 

PIL Section 2 Warnings and Precautions

 

[.....]

 

Use of sanitary pads is recommended. If tampons or menstrual cups are used, you should change them with care so as not to pull the threads of Kyleena.

 

PIL Section 4 Possible side effects

 

[.....]

 

Common side effects: may affect up to 1 in 10 people

Common side effects added:

'decreased libido'

'dizziness'

'increased weight'

 

 

[.....]

 

<'hair loss' re-located to maintain the same order of the adverse events as in the SmPC.>

 

[.....]

 

<Update of Reporting of Side Effects details updated for Ireland in line with Appendix V>:

 

HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. W website: www.hpra.ie.; E-mail: medsafety@hpra.ie.

 

[.....]

 

PIL Section 6:

This leaflet was last revised in April 2019 July 2020

Updated on 7 July 2020

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

To implement the outcome of the finished PSUSA procedure of all levonorgestrel-containing products (PSUSA/00001856/ 201905). For Kyleena additional wording for SmPC section 4.8 and PL section 3 and 4 has to be introduced.

The HPRA details for the reporting of side effects have also been updated.

 

SmPC Section 4.8

Tabulated summary of adverse events

 [.....]

'Deceased libido' added as a common side effect under System Organ Class: Psychiatric disorders.

'Dizziness' added as a common side effect under System organ Class: Vascular disorders

'Increased weight' added as a common side effect under System Organ Class: Investigations

[.....]

 

<Update of Reporting of Side Effects details updated for Ireland in line with Appendix V>:

HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. W  website: www.hpra.ie.; E-mail: medsafety@hpra.ie.

[.....]

 

SmPC section 10, Date of revision of the text:

April 2019 June 2020

 

Updated on 7 July 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

To implement the outcome of the finished PSUSA procedure of all levonorgestrel-containing products (PSUSA/00001856/ 201905). For Kyleena additional wording for SmPC section 4.8 and PL section 3 and 4 has to be introduced.

The HPRA details for the reporting of side effects have also been updated.

 

PIL Section 2 Warnings and Precautions

[.....]

Use of sanitary pads is recommended. If tampons or menstrual cups are used, you should change them with care so as not to pull the threads of Kyleena.

[.....]

 

PIL Section 4 Possible side effects

[....]

Common side effects: may affect up to 1 in 10 people

Common side effects added:

'decreased libido'

'dizziness'

'increased weight'

[.....]

 

[.....]

<'hair loss' re-located to maintain the same order of the adverse events as in the SmPC.>

[.....]

 

<Update of Reporting of Side Effects details updated for Ireland in line with Appendix V>:

HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. W website: www.hpra.ie.; E-mail: medsafety@hpra.ie.

[.....]

 

PIL Section 6:

[.....]

This leaflet was last revised in April 2019 July 2020

[.....]

 

Updated on 20 June 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 19 June 2019

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Update to warnings and prcautions due to PRAC reccommendation

Updated on 10 December 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 10 December 2018

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Updated on 17 May 2018

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SmPC has updated as a result of the final study report for the subgroup of EURAS-IUD. The perforation text under subsection ‘Insertion and removal/ replacement’ was adapted to current medical practice, the average estimated in vivo release rate over the 1st year was added to section 5.2 and text under 4.8 regarding sepsis was adjusted to reflect the class effect. Editorial spelling changes also made.

Updated on 26 April 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 4 April 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 April 2018 SPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 6.3, the shelf-life has been changed from 2 to 3 years.

In section 10, the revision date has been updated to March 2018.

Updated on 4 April 2017 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 4 April 2017

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 April 2017 PIL

Reasons for updating

  • New PIL for new product
  • HCP brochure - diferentiation IUS+ectopic pregnancyRisk Minimisation Materials

    files-icon(Click to Download)